Format

Send to

Choose Destination
Bonekey Rep. 2015 Oct 7;4:744. doi: 10.1038/bonekey.2015.113. eCollection 2015.

Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.

Author information

1
National and Kapodistrian University of Athens, School of Medicine , Athens, Greece.
2
Department of Rheumatology, Edouard Herriot Hospital, Hospices Civils de Lyon , Lyon, France ; INSERM, Research Unit UMR1033, UFR de Médecine Lyon-Est (domaine Laennec) , Lyon, France ; Université de Lyon , Lyon, France.
3
INSERM, Research Unit UMR1033, UFR de Médecine Lyon-Est (domaine Laennec) , Lyon, France ; Université de Lyon , Lyon, France.

Abstract

Skeletal lesions contribute substantially to morbidity and mortality in patients with cancer. The disease manifestation course during metastatic bone disease is driven by tumour cells in the bone marrow, which alter the functions of bone-resorbing (osteoclasts) and bone-forming (osteoblasts) cells, promoting skeletal destruction. Successful therapeutic strategies for the treatment of metastatic bone disease include bisphosphonates and denosumab that inhibit osteoclast-mediated bone resorption. Inhibitors of cathepsin K, Src and activin A are under clinical investigation as potential anti-osteolytics. In this review, we describe current knowledge and future directions of antiresorptive therapies that may reduce or prevent destructive bone lesions from solid tumours and multiple myeloma.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center